Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Net Margin (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Net Margin for 15 consecutive years, with 11.83% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 488.0% to 11.83% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.89% through Dec 2025, down 780.0% year-over-year, with the annual reading at 12.89% for FY2025, 781.0% down from the prior year.
  • Net Margin hit 11.83% in Q4 2025 for Corcept Therapeutics, up from 9.32% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 33.96% in Q3 2022 to a low of 9.32% in Q3 2025.
  • Historically, Net Margin has averaged 22.21% across 5 years, with a median of 23.12% in 2023.
  • Biggest five-year swings in Net Margin: crashed -1639bps in 2022 and later surged 696bps in 2023.
  • Year by year, Net Margin stood at 32.44% in 2021, then crashed by -51bps to 16.04% in 2022, then surged by 43bps to 23.0% in 2023, then fell by -27bps to 16.71% in 2024, then fell by -29bps to 11.83% in 2025.
  • Business Quant data shows Net Margin for CORT at 11.83% in Q4 2025, 9.32% in Q3 2025, and 17.8% in Q2 2025.